Back to homepage

Haematology and Oncology

Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review

Authors: Xenophon Kassianides BSc (Hons), MBBS, MRCP(UK), Sunil Bhandari MBChB, MRCP, FRCP, PhD, M Clin Edu, FHEA

This review focues on the links between iron and phosphate metabolism, the most recent comparative studies between third-generation i.v. iron compounds, the important role of fibroblast growth factor 23 (FGF23), and the impact of hypophosphataemia on the patient. This review also presents an algorithm that can be used in patients requiring i.v. iron in anticipation of potential hypophosphataemia.

More

Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia

Authors: Diego Conde-Royo MD, Luis Miguel Juárez-Salcedo MD, Samir Dalia MD

This article reviews the unique toxicities and adverse effects of blinatumomab and inotuzumab ozogamicin and provide recommendations for prevention of adverse effects as well as the management options for each medication.

More

TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of life in heavily pretreated elderly patients: a real-life study

Authors: Giuseppe Cicero MD PhD, Raffaele Addeo MD, Rossella De Luca PhD, Giuseppe Lo Re MD PhD, Leonardo Gulotta MD, Pierenrico Marchesa MD, Gaspare Gulotta MD PhD

This study evaluates the safety and
efficacy of TAS-102 in heavily pretreated elderly patients with
metastatic colorectal cancer.

More

Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study

Authors: Hae-Jin Suh Oh MD, Ángeles Flórez Menéndez PhD, Víctor Sacristán Santos MD, Francisca Fernández Ribeiro PharmD, Lucía Vilanova-Trillo DNP, Manuel Constenla Figueiras PhD, Manuel Pereiro Ferreiros PhD

This study evaluates the impact of cutaneous adverse events on quality of life in outpatients receiving anticancer drugs and aims to determine the differences in quality of life between conventional chemotherapy versus targeted therapies.

More

Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) epidemiology and treatment pathway in Spain: new insights for an accurate description

Authors: Paolo D’Agostino MSc, Alan Kent BSc (Hons), Eric Sharp MRSB, Fabian Schmidt Dipl.Kfm, Marco Turini MSc

This study aims to (1) provide an estimate for the prevalence of treated mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) patients in Spain, (2) describe the Spanish patient treatment pathways for MF-CTCL, including quantification of the distribution of patients between primary, secondary and tertiary care institutions, and (3) investigate and quantify the treatment preferences of physicians.

More